Heyll A, Aul C, Gogolin F, Thomas M, Arning M, Gehrt A, Hadding U
Abteilung für Hämatologie, Universität Düsseldorf, FRG.
Ann Hematol. 1991 Dec;63(6):328-32. doi: 10.1007/BF01709656.
Adult respiratory distress syndrome (ARDS) in patients suffering from acute leukemia usually occurs during chemotherapy-induced neutropenia. In addition, intensified chemotherapy with high-dose cytosine arabinoside and mediastinal irradiation may contribute to the development of ARDS. This complication is usually refractory to conservative treatment with antibiotics, steroids, and mechanical ventilation. In this report, we describe a 25-year-old patient with acute lymphoblastic leukemia who developed ARDS during the phase of chemotherapy-induced neutropenia. Subcutaneous administration of granulocyte colony-stimulating factor (G-CSF) at doses of 300-600 micrograms/day led to a prompt increase of peripheral granulocyte counts. With resolution of neutropenia, respiratory function gradually improved, and mechanical ventilatory support was stopped after 2 weeks. From this observation we surmise that the application of G-CSF may be an effective therapeutic approach for preventing the fatal outcome of ARDS in leukemia patients with bone marrow aplasia.
急性白血病患者的成人呼吸窘迫综合征(ARDS)通常发生在化疗引起的中性粒细胞减少期间。此外,大剂量阿糖胞苷强化化疗和纵隔照射可能促使ARDS的发生。这种并发症通常对抗生素、类固醇和机械通气的保守治疗无效。在本报告中,我们描述了一名25岁的急性淋巴细胞白血病患者,在化疗引起的中性粒细胞减少阶段发生了ARDS。皮下注射剂量为300 - 600微克/天的粒细胞集落刺激因子(G-CSF)导致外周粒细胞计数迅速增加。随着中性粒细胞减少的缓解,呼吸功能逐渐改善,2周后停止了机械通气支持。从这一观察结果我们推测,应用G-CSF可能是预防骨髓再生障碍的白血病患者发生ARDS致命结局的一种有效治疗方法。